Shinya Yamanaka's 2006 discovery of induced pluripotent stem cell (iPS) reprogramming—achieving pluripotency by introducing just four transcription factors into adult cells—revolutionised regenerative medicine by decoupling pluripotent stem cell research from embryonic sources. This breakthrough earned him the 2012 Nobel Prize in Physiology or Medicine, shared with John Gurdon. iPS cells opened pathways for patient-specific cellular models and theoretically unlimited cell sources for transplantation without immune rejection. Clinically, iPS-derived products are now advancing through trials for macular degeneration, Parkinson's disease, and cardiac dysfunction. Yamanaka's methodology simultaneously addressed an ethical bottleneck and expanded research capacity globally; many jurisdictions with restrictions on embryonic research could now pursue pluripotent stem cell science. The technology remains dependent on efficient reprogramming protocols and robust safety validation—particularly tumour risk from residual pluripotent cells—but has fundamentally shifted the trajectory of regenerative medicine from cell sourcing to cell engineering. His legacy extends beyond iPS cells themselves to the broader principle that cellular identity is plastic and reversible, a paradigm that influences how scientists approach tissue repair and disease modelling today.
Most clinical uses of stem cells remain investigational — check the evidence and approval status for your condition before acting on any clinic's claims.
Sources & profiles
← All pioneers · Conditions compared →